SCHEMBL893997

SCHEMBL893997

NC(=O)c1ccc(Cl)nc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.42
CASP1 P29466 4/20 0.40
NNMT P40261 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 3/20 0.38
SLC6A12 P48065 1/20 0.38
POLB P06746 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
SIRT6 Q8N6T7 1/20 0.36
PARP1 P09874 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IKBKB O14920 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664846 0.81 IKBKB (0.46) KMT2AATMCASP1NNMTLMNA
SCHEMBL392559 0.81 IKBKB (0.46) KMT2AATMCASP1NNMTLMNA
SCHEMBL18941668 0.81 KMT2A (0.41) KMT2AATMCASP1NNMTLMNA
SCHEMBL56617 0.80 SMN1; SMN2 (0.50) KMT2ACASP1LMNAALDH1A1SLC6A12
SCHEMBL29378242 0.80 SMN1; SMN2 (0.50) KMT2ACASP1LMNAALDH1A1SLC6A12
SCHEMBL671978 0.80 SLC6A12 (0.38) LMNAALDH1A1SLC6A12MAPTGAA
SCHEMBL29375536 0.80 SLC6A12 (0.38) LMNAALDH1A1SLC6A12MAPTGAA
SCHEMBL3648999 0.79 NNMT (0.58) KMT2AATMNNMTLMNAALDH1A1
SCHEMBL29943583 0.79 KMT2A (0.40) KMT2AATMCASP1NNMTLMNA
SCHEMBL5190356 0.79 POLB (0.52) KMT2AATMCASP1NNMTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12202813-B2 Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide BEIJING INNOCARE PHARMA TECH CO., LTD (CN) 2025-01-21 US claimed
EP-3931182-A1 PROCESS FOR PREPARING 6- (1-ACRYLOYLPIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) NICOTINAMIDE Beijing InnoCare Pharma Tech Co., Ltd. (CN) 2022-01-05 EP claimed
CN-113698342-B Preparation method of 2, 6-dichloronicotinic acid as key intermediate heterocyclic compound of orbetinib 南京恒远科技开发有限公司 2021-12-31 CN claimed
US-20210380555-A1 PROCESS FOR PREPARING 6-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDE BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2021-12-09 US claimed
CN-113698342-A Preparation method of 2, 6-dichloronicotinic acid as key intermediate heterocyclic compound of orbetinib 南京恒远科技开发有限公司 2021-11-26 CN claimed
CN-113454066-A Process for the preparation of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide 北京诺诚健华医药科技有限公司 2021-09-28 CN claimed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-12-18 US disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 US disclosed
EP-4602041-A1 HPK1 INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-08-20 EP disclosed
US-20250250286-A1 FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS BETA PHARMA INC (US) 2025-08-07 US disclosed
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) 2025-05-22 US disclosed
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-13 US disclosed
EP-1087963-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 Chiron Corporation (US) 2001-04-04 EP disclosed
WO-1999065897-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 1999-12-23 WO disclosed
US-5571912-A Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1996-11-05 US disclosed
EP-0482481-A1 Method for the preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1992-04-29 EP disclosed
EP-0482481-A1 Method for the preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1992-04-29 EP disclosed
US-4100283-A Growth promoting feed additive oxadiazines CIBA-GEIGY CORPORATION (US) 1978-07-11 US disclosed
US-4064243-A Heterocyclic-substituted 1,3,5-oxadiazin-2-one compounds useful for combatting coccidiosis CIBA-GEIGY CORPORATION (US) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250286-A1 FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS KRAS, NRAS, HRAS KMT2A 2575/4885ATM 1843/4885CASP1 2260/4885
US-20250084064-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS SCN8A, SCN2A, SCN1A KMT2A 1842/4885ATM 4327/4885CASP1 1936/4885
US-20250163016-A1 PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF KDM1B, KDM1A, EZH2 KMT2A 44/4885ATM 3831/4885CASP1 1582/4885
US-12202813-B2 Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide NAMPT, NNT, NAPRT KMT2A 2421/4885ATM 1620/4885CASP1 492/4885
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS KMT2A 2069/4885ATM 2171/4885CASP1 3637/4885
US-12440491-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS KMT2A 2069/4885ATM 2171/4885CASP1 3637/4885
US-20210380555-A1 PROCESS FOR PREPARING 6-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDE NAMPT, NNT, NAPRT KMT2A 2421/4885ATM 1620/4885CASP1 492/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A KMT2A 102/4885ATM 521/4885CASP1 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.